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Histamine H3 receptors are widely distributed Gi-coupled receptors whose activation reduces neuronal 
activity and inhibits release of numerous neurotransmitters. Although these receptors are abundantly 
expressed in the striatum, their modulatory role on activity-dependent dopamine release is not well 
understood. Here, we observed that histamine H3 receptor activation indirectly diminishes dopamine 
overflow in the ventral striatum by reducing cholinergic interneuron activity. Acute brain slices from 
C57BL/6 or channelrhodopsin-2-transfected DAT-cre mice were obtained, and dopamine transients 
evoked either electrically or optogenetically were measured by fast-scan cyclic voltammetry. The H3 
agonist α-methylhistamine significantly reduced electrically-evoked dopamine overflow, an effect 
blocked by the nicotinic acetylcholine receptor antagonist dihydro-β-erythroidine, suggesting 
involvement of cholinergic interneurons. None of the drug treatments targeting H3 receptors affected 
optogenetically evoked dopamine overflow, indicating that direct H3-modulation of dopaminergic axons 
is unlikely. Next, we used qPCR and confirmed the expression of histamine H3 receptor mRNA in 
cholinergic interneurons, both in ventral and dorsal striatum. Activation of H3 receptors by α-
methylhistamine reduced spontaneous firing of cholinergic interneurons in the ventral, but not in the 
dorsal striatum. Resting membrane potential and number of spontaneous action potentials in ventral-
striatal cholinergic interneurons were significantly reduced by α-methylhistamine. Acetylcholine release 
from isolated striatal synaptosomes, however, was not altered by α-methylhistamine. Together, these 
results indicate that histamine H3 receptors are important modulators of dopamine release, specifically in 
the ventral striatum, and that they do so by decreasing the firing rate of cholinergic neurons and, 
consequently, reducing cholinergic tone on dopaminergic axons. 




Histaminergic neurons originate in the tuberomammilary nucleus in the posterior hypothalamus (Wilcox 
and Seybold, 1982; Panula et al., 1984; Watanabe et al., 1984; Wouterlood et al., 1986) and project 
throughout most areas of the brain, including the dorsal and ventral striatum (Watanabe et al., 1984; 
Steinbusch et al., 1986). Of the four histamine receptors known to date, histamine H1, H2 and H3 receptors 
are densely expressed in the striatum (Palacios et al., 1979; Ruat et al., 1990; Pollard et al., 1993; Pillot et 
al., 2002), and activation of these receptors has profound regulatory effects on signaling by the diverse 
components of striatal circuitry (Bolam and Ellender, 2015). Histamine H3 receptors serve a 
predominantly inhibitory role by signaling through Gi protein (Arrang et al., 1983), and have a high 
degree of constitutive activity (Morisset et al., 2000). In the striatum, their activation reduce cortico-
thalamic excitatory input onto medium-spiny neurons (Ellender et al., 2011), and may counteract some of 
the excitatory effects seen with histamine H1 and H2 receptor activation (Sittig and Davidowa, 2001). 
Dopaminergic neurons are located mostly in the mesencephalon, which is sub-divided in the substantia 
nigra (SN) and ventral tegmental area (VTA). Neurons in the SN densely innervate the dorsal striatum, 
while those located in the VTA project primarily to the ventral striatum and cortex. Although there is 
substantial anatomical overlap between the dopaminergic and histaminergic systems, the knowledge on 
how these systems interact, both at the cellular and behavioral levels, is still incomplete (Ellenbroek, 
2013). Histamine H3 receptors are capable of modulating methamphetamine or amphetamine self-
administration (Munzar et al., 2004; Vanhanen et al., 2015), alcohol consumption and reward (Nuutinen 
et al., 2011), stereotypic behavior (Kitanaka et al., 2011; Mahmood et al., 2012) and L-DOPA-induced 
dyskinesia (Nowak et al., 2008; but see Papathanou et al., 2014), all of which are thought to be mediated, 
at least in part, by striatal dopamine release. Studies show that D1 and H3 receptors form heteromers in the 
striatum and this interaction is capable of curbing the levels of phosphorylated MAPK (Moreno et al., 
2014), D1-induced accumulation of cAMP (Sanchez-Lemus and Arias-Montano, 2004) and D1-induced 
reduction of dopamine release (Alfaro-Rodriguez et al., 2013). Conversely, histaminergic neurons express 
D1 and D2 receptors, whose activation promotes increased firing activity, histamine release, and 
wakefulness (Yanovsky et al., 2011). These results denote a concerted interplay between dopamine and 
histamine, leading to complex physiological and pathophysiological ramifications. 
Elsewhere in the brain histamine H3 receptors have a well described role as pre-synaptic autoreceptors 
and heteroreceptors, modulating release of not only histamine (Arrang et al., 1985), but also glutamate 
(Brown and Haas, 1999), GABA (Yamamoto et al., 1997), serotonin (Threlfell et al., 2004) and 
acetylcholine (Clapham and Kilpatrick, 1992), among others. However, to date, studies that investigated 
 4 
 
the effects of histamine H3 receptors on dopamine release have generated conflicting data, indicating 
either no modulation (Fox et al., 2005; Giannoni et al., 2010; Aquino-Miranda et al., 2015), or decreased 
dopamine release upon activation of H3 receptors (Schlicker et al., 1993). This could be due to regional 
differences in the effect of H3 receptors in different parts of the striatum or to the fact that H3 receptors act 
indirectly to regulate dopamine release, something that could be missed depending on the methods used. 
Here, we employed a combination of pharmacological and optogenetics tools, allied to the voltammetric 
measurement of dopamine to investigate the hypothesis that histamine H3 receptors modulate dopamine 
release in the dorsal and ventral striatum of acutely isolated brain slices. We found that activation of H3 
receptors reduces dopamine release, but only in the ventral striatum. We further discovered that this effect 
is achieved indirectly, via H3 receptors expressed in cholinergic interneurons, rather than H3 receptors 
located on dopaminergic axons. We anticipate that histamine H3 ligands capable of modulating dopamine 
release in the ventral striatum could be good candidates for treatment of diseases where dopamine 





Animals and reagents 
All procedures were approved by the animal ethics committee (CDEA) of the Université de Montréal. 
C57BL/6 mice used in the assessment of electrically stimulated dopamine overflow were purchased from 
Charles River (Senneville, Quebec, Canada). DAT-cre mice (129/ Sv/J background) used in the 
optogenetics experiments were kindly donated by Dr. Zhuang from the University of Chicago (Zhuang et 
al., 2005). TH-EGFP/21-31 (TH-GFP) transgenic mice used for purification of dopaminergic neurons 
were kindly donated by Dr. Katzuto Kobayashi from Fukushima Medical University, Japan (Sawamoto et 
al., 2001). C57BL/6JRccHsd mice used for synaptosomes preparations were purchased from Envigo 
(Horst, Netherlands). Vglut3-cre transgenic mice (Tg(Slc17a8-icre)1Edw/SealJ, Jax strain 018147) were 
originally donated by Drs Robert Edwards and Rebecca Seal, and were crossed with tdTomatoflx mice 
(B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J, Jax stock number 007914) to generate Vglut3-
tdTomato mice (homozygous for tdTomato). Animals were group-housed in Plexiglas cages with 
environment controlled at 23 ºC and 50% humidity, food and water ad libitum and a light cycle of 12 
hours (lights on at 6:00 am). All reagents and drugs were purchased from Sigma-Aldrich (St.-Louis, MO, 
USA) except when otherwise noted. 
Mesencephalic virus injection to deliver Channelrhodopsin-2 
Two-month old male DAT-cre heterozygous mice were anesthetized with isoflurane (AErraneTM) and 
fixed on a stereotaxic frame (Stoelting, Wood Dale, IL, USA). The fur on the top of the head was 
removed and the surgical area disinfected with iodine alcohol. Throughout the entire procedure, artificial 
tears (EquateTM) were applied to the eyes and a heat pad was placed under the animal and kept at 37 ºC. 
Next, 0.05 ml of bupivacaine (MarcaineTM) was subcutaneously injected at the surgical site, an incision of 
about 1 cm made with a scalpel blade and the cranial bones exposed. Using a dental burr, two holes of 
approximately 1 mm diameter were drilled above the VTA (AP: - 3.3 mm, ML: ± 0.4 mm) (Franklin and 
Paxinos, 2008). Next, a blunt 34 G needle coupled to a water-filled polyethylene tube and a Hamilton 
syringe (Reno, NV, USA) was loaded with 0.9 % NaCl solution containing 1 x 1011 VGP of AAV-2 
EF1α-DIO-hChR2(H134R)-EYFP-WPRE-pA (University of North Carolina Gene Therapy Center Vector 
Core, Chapel Hill, NC, USA). A small air bubble (0.1 µL) was kept at the interface between water and 
virus solution. The needle was slowly inserted in the VTA (DV: - 4.7 mm) and 0.4 µL of virus solution 
was injected at a rate of 0.1 µL per min using a syringe pump (Harvard Apparatus, Holliston, MA, USA). 
The needle was then withdrawn 0.2 mm and the injection repeated. After the second injection, the needle 
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was left in its place for 10 min to allow virus diffusion. Successful injections were confirmed by the 
movement of the air bubble in the polyethylene tube. Then, the needle was slowly withdrawn and the 
procedure repeated in the contralateral side. Once bilateral injections were completed, the surgery wound 
was sutured and a subcutaneous injection of the anti-inflammatory carprofen (RimadylTM, 4.4 mg/kg) was 
given. Animals were allowed to recover in their home cage and closely monitored for 24 hours. A second 
dose of carprofen was given if deemed necessary. At least three weeks after injection were allowed for 
virus expression, at which time experiments were performed. 
Acute brain slices preparation and solutions.  
Brain slicing was performed as described in Ting et al. (2014) with minor modifications. In brief, three to 
five months old mice were anesthetized with pentobarbital (90 mg/kg i.p.) and transcardially perfused 
with ice-cold N-Methyl-D-Glucamine-buffer (NMDG-buffer, in mM: NMDG 93, KCl 2.5, NaH2PO4 1.2, 
NaHCO3 30, HEPES 20, Glucose 25, sodium ascorbate 5, thiourea 2, sodium pyruvate 3, MgSO4 10 and 
CaCl2 0.5 with pH adjusted to 7.35 with 5N HCl, 300 mOsm/kg and saturated with 95% O2-5% CO2). 
Their brain was quickly removed after gentle opening of the skull and placed in ice-cold continuously 
oxygenated NMDG-buffer. 300 µm thick coronal brain slices containing the most rostral portion of the 
striatum (Bregma coordinates: from 1.42 to 0.14 mm) were prepared with a VT1000S vibrating 
microtome (Leica Microsystems Inc., Nussloch, Germany) in ice-cold NMDG-buffer, and then 
transferred to 32 ºC NMDG-buffer for 15 min. Next, slices were placed at room temperature in a custom-
made submerged recovery chamber containing artificial cerebral spinal fluid (aCSF, in mM: NaCl 124, 
KCl 2.5, NaH2PO4 1.2, NaHCO3 24, HEPES 5, Glucose 12.5, MgSO4 1.3 and CaCL2 2.4 pH adjusted to 
7.35 with 5N NaOH, 300 mOsm/kg and saturated with 95% O2-5% CO2) for at least 1 hour. Slices were 
transferred to a custom-made submerged recording chamber superfused with aCSF (approximately 1 
mL/min, gravity driven) and maintained at 32 ºC with a TC-324B single channel heater controller 
(Warner Instruments Inc., Hamden, CT, USA). Drugs were reconstituted from stock solutions into aCSF 
each experimental day. 
Electrochemical recordings.  
Action potential-induced dopamine overflow transients were evoked either by electrical stimulation with 
a bipolar electrode (Plastics One, Roanoke, VA, USA) or by a blue light emitting diode (LED, Luxeon, 
Brantford, Ontario, Canada) connected to a 1 mm diameter optic fiber (Edmond Optics, Barrington, NJ, 
USA). Transients were detected by fast-scan cyclic voltammetry (FSCV) using a carbon-fiber electrode 
placed into either the dorsal or ventral striatum, approximately 100 µm below the surface. Carbon-fiber 
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electrodes were fabricated as previously described (Martel et al., 2011). Briefly, carbon fibers (Cytec 
Industries Inc., NJ, USA) of approximately 5 µm in diameter were aspirated into ethanol-cleaned glass 
capillaries (1.2 mm O.D., 60.68 mm I.D., 4 inches long; A-M Systems, WA, USA). The glass capillaries 
were then shaped using a P-2000 micropipette puller (Sutter Instruments, Novato, CA, USA), dipped into 
90˚C epoxy for 30 s (Epo-Tek 301, Epoxy Technology, MA, USA) and cleaned in hot acetone for 3 s. 
The electrodes were heated at 100˚C for 12 h and 150˚C for 5 days. Before and after usage, electrodes 
were cleaned with isopropyl alcohol to promote greater sensitivity. Carbon fibers were cut using a scalpel 
blade under direct visualization to obtain a maximal basal current in aCSF between 100 and 180 nA. 
Electrodes were finally selected for their sensitivity to dopamine using in vitro calibration with 1 µM 
dopamine in aCSF before each experiment. The potential of the carbon fiber electrode was scanned at a 
rate of 280 V/s according to a 10 ms triangular voltage waveform (-400 to 1000 mV vs Ag/AgCl 
reference) with a 10 Hz sampling frequency using an Axopatch 200B amplifier (Molecular Devices, 
Sunnyvale, CA, USA). Data were acquired using a DigiData 1440A analog to digital board converter 
(Molecular Devices) connected to a computer running Clampex 10 (Molecular Devices). Electrical 
stimuli (1 ms long monophasic pulses of 400 µA) were generated by a S-900 stimulator (Dagan 
Corporation, Minneapolis, MN, USA) every 2 min to evoke dopamine release for a total of 10 min. 
Recordings in which peak dopamine overflow showed deviation greater than 20% between the first and 
the fifth response to single stimulation were considered unstable and not used for further analyses (n = 6). 
Next, single pulse stimuli were intercalated with paired pulses (100 Hz) every 2 min, and a baseline 
recorded for 12 min. Slices were then superfused with aCSF containing the H3 receptor agonist α-
methylhistamine (1 µM, Tocris, Bristol, United Kingdom), the H3 receptor inverse agonist thioperamide 
(10 µM, Tocris) or vehicle for 48 min. All values obtained thereafter were transformed to the baseline 
average. A subset of slices was recorded in presence of the nicotinic receptor antagonist dihydro-β-
erythroidine (1 µM, Tocris) throughout the experiment. For the optogenetic experiments, 1 ms stimuli of 
20 mW/mm2 and 480 nm wave length were generated by a home-built LED controller coupled to a 1 W 
blue-light emitting diode attached to an optic fiber. Optical stimulation was performed near the recording 
site. Stimulating and recording parameters were the same as above, with the exception of paired pulses 
were triggered at 10 Hz instead of 100 Hz in order to accommodate the slower kinetics of 
channelrhodopsin-2. Recordings were done either in the dorsolateral striatum (referred here as dorsal 
striatum) or in the core portion of the nucleus accumbens (referred here as ventral striatum). 
Cells preparation and Fluorescence Activated Cell Sorting (FACS) 
Transgenic mice expressing the eGFP gene in monoaminergic neurons under control of the TH promoter 
(TH-GFP mice) and transgenic mice expressing the tdTomato gene in glutamatergic neurons under 
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control of the VGluT3 promoter (VGluT3-tdTomato mice) were used. Mice were anesthetized with 
sodium pentobarbital (90 mg/ml, i.p.) and perfused with an oxygenated (100% O2) NMDG-buffer as 
described above. The brain was extracted and transferred to a dish containing the NMDG-buffer to dissect 
the SN and VTA, or the dorsal and ventral striatum. Each piece of tissue was incubated with 0.8 mg/ml 
trypsin (Gibco, Waltham, MA, USA) in an oxygenated (100% O2) PIPES-buffered saline (in mM: 115 
NaCl, 5 KCl, 4 MgCl2, 1 CaCl2, 25 glucose, 20 piperazine-N,N’-bis-[2-ethanesulfonic acid]) at pH 7.0 for 
30 min at 30 ºC. The tissue was then transferred briefly to the same buffer containing fetal bovine serum 
(FBS) 10% to arrest the action of trypsin. The tissue was placed for 90 min in the same oxygenated 
PIPES solution at room temperature, then triturated delicately with a 5 ml glass pipette and centrifuged. 
After this, cells were recovered by resuspension of the pellet in PBS containing 1% FBS. Finally, eGFP-
positive neurons or tdTomato-positive neurons were purified by FACS and directly placed in a Trizol-
Reagent solution (Ambion, Waltham, MA, USA). The samples were stored at -80 ºC until RNA 
extraction. 
Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) 
Primers for the transcript variant 1 of mus musculus’ H3 receptor (H3R, NCBI Reference Sequence: 
NM_133849.3) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were designed with the 
Primers 3 and Vector NTI software. Primers were synthetized by Alpha DNA (Montreal, Quebec, 
Canada). Primers for RT-qPCR in experiments on TH-eGFP and VGluT3-tdTomato mice were as follow: 
H3R 5’-tgggtgccttctgcatc-3’ and 5’-gaggaggcacacagtaggtag-3’; (GAPDH) 5’-ggaggaaacctgccaagtatga-3’ 
and 5’-tgaagtcgcaggagacaacc-3’. Validation of the primers was carried out by comparing primer 
sequences to the nucleotide sequence database in GenBank using BLAST 
(www.ncbi.nlm.nih.gov/BLAST/). RNA extraction was performed with the Rneasy Mini kit (Quiagen, 
Toronto, Ontario, Canada) according to the manufacturer’s instructions. The concentration and the purity 
of the RNA from dopaminergic and cholinergic neurons were determined using a NanoDrop 1000 
(Thermo Scientific, Waltham, MA, USA). Total purified RNA (40 ng) was reverse-transcribed in a total 
of 20 µl including 1 µl of dNTP, 1 µl of random hexamer, 4 µl of 5X buffer 5X, 2 µl of dithiothreitol 
(DTT), 1 µl of RNAse-Out and 1 µl of the Moloney Murine Leukemia Virus reverse transcriptase enzyme 
(MML-V). RT-qPCR was carried out in a total of 15 µl, consisting of 3 µl cDNA, 7.5 µl SYBER green 
PCR master mix (Quanta Biosciences, Gaithersburg, MD, USA), 10 µM of each primer, completed to 15 
µl with RNA-free water. RT-qPCR was performed on a Light Cycler 96 (Roche Diagnostics, Laval, 
Quebec, Canada) using the following protocol: 10 min at 95 ºC; 40 cycles of 30 sec at 95 ºC, 40 sec at 57 
ºC and 40 sec at 72 ºC; 1 cycle of 15 sec at 95 ºC, 15 sec 55 ºC and 15 sec 95 ºC. The efficiency of the 
reaction E=10(-1/slope) -1 was calculated from the slope of the linear relationship between the log values of 
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the RNA quantity and the cycle number (Ct) in a standard curve. Calculation of relative mRNA levels 
was performed by using the 2(-ΔΔCt) formula (Livak and Schmittgen, 2001), where the Ct value of the 
mRNA level for H3R were normalized to the Ct value of GAPDH in the same sample. Ct values used 
were the averages of triplicate repeats. Melt-curves of tissue homogenate indicated specific products after 
H3 receptor qPCR mRNA amplification, attesting the adequate quality of the primers chosen (not shown). 
Loose cell-attached electrophysiological recordings 
For recordings in the ventral striatum, acute brain slices from male and female VgluT3-tdTomato mice 
were prepared as described above and placed in a recording chamber under an Olympus upright 
microscope continuously perfused with oxygenated aCSF and kept at 32 ºC. In the striatum, the only 
population of neurons expressing VgluT3 is composed of cholinergic interneurons (Gras et al., 2002). 
Ventral-striatal cholinergic interneurons were identified by their fluorescence and spontaneous activity. A 
borosilicate glass-pulled electrode (3-6 MΩ resistance) filled with aCSF was placed nearby the target cell, 
and gentle negative pressure was applied to facilitate the formation of a membrane seal.  Loose cell-
attached voltage-clamp recordings were amplified at 10 x gain and low-pass filtered at 2 kHz in a 
MultiClamp 700B Amplifier, and digitized at 50 kHz in a 1440 DigiData analog-to-digital converter 
board. Signals were recorded with Clampex 10 and analyzed in Clampfit 10 (all from Molecular 
Devices). Spontaneous events were detected using a threshold greater than four standard deviations of 
noise. Cells with average spontaneous activity lower than 0.1 Hz and greater than 12 Hz were deemed 
unhealthy and discarded (n = 8). After a 5 min baseline, slices were superfused with aCSF containing α-
methylhistamine (1 µM), thioperamide (10 µM) or vehicle for 15 min. Event frequency was averaged at 1 
min intervals and transformed to the average of baseline (first 5 min) to yield the normalized event 
frequency, an indicator of how frequency changes over time. Instant event frequencies of the last 5 min of 
the experiment were broken into 0.5 Hz bins to define frequency/activity histograms. These values were 
then transformed to the total number of events during those 5 min to yield the relative event frequency, an 
indicator of how the patterns of firing frequencies are affected by each drug treatment.  
Recordings in the dorsal striatum were performed in similar conditions, with the exception that slices 
were obtained from male C57BL/6 mice. Cholinergic interneurons were identified by their morphology 
(i.e. scarce, evenly distributed, very large neurons) and spontaneous firing when in loose cell-attached 
configuration. 
Whole-cell electrophysiological recordings 
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Slices were obtained from male C57BL/6 mice and placed in a recording chamber as described above. 
Cholinergic interneurons were selected by their morphology. A pipette filled with solution containing, in 
mM; 2.25 KCl, 125.3 KMeSO3, 10 HEPES, 0.1 EGTA acid, 1 MgCl2, 2 MgATP, 0.5 Na-GTP, 5 Na2-
phospocreatine, 2 Na-pyruvate, 2 malate, neurobiotin, pH 7.2 with KOH (295 mOsm adjusted with 
KMeSO3) was placed next to the target cell. Gentle negative pressure was applied to the pipette to induce 
the formation of a tight membrane seal. After obtaining whole-cell configuration, the identity of 
cholinergic interneurons was confirmed by their electrophysiological characteristics: cell capacitance 
between 60 and 150 pF, resting membrane potential around -55 mV and occurrence of spontaneous 
action-potentials followed by large, transient, hyperpolarization periods. Next, about 5-7 min were 
elapsed to allow cell stabilization. A second pipette connected to a Picospritzer III (Parker Hannifin, 
Cleveland OH, USA) and containing either aCSF alone or aCSF with α-methylhistamine (10 µM) was 
placed in the vicinity of the cell being recorded. Next, resting membrane potential and spontaneous 
activity were recorded in current clamp (I0) mode for a period of 1 min. Then, drug treatment was 
delivered by applying 2 PSI for 30s to the drug-containing pipette. Resting membrane potential and 
spontaneous activity were measured during the 30s drug ejection and for additional 30s (1 min total). 
Action potentials were identified using a peak template in Axograph X (Axon Instruments, Foster City, 
CA, USA). Cell neurochemical identity was confirmed by co-immunostaining the neurobiotin-filled cells 
for streptavidin and choline acetyltransferase (ChAT).  
Immunohistochemistry and imaging 
Hemisected brains from the above experiments were immediately fixed in 4% paraformaldehyde solution 
for at least 7 days at 4 ºC. Coronal slices (50 µm thick) containing the striatum or mesencephalon were 
prepared in a vibrating microtome (Leica) and placed in PBS. Striatal and mesencephalic slices from 
virus-injected DAT-cre mice had non-specific sites blocked with goat serum, and were incubated 
overnight with mouse anti-TH antibody (1:1000, Millipore, Billerica, MA, USA) and rabbit anti-GFP 
antibody (1:2000, Cedarlane, Burlington, Ontario, Canada). Slices from VGluT3-tdTomato mice had non-
specific sites blocked with donkey serum, and were subsequently incubated with rabbit anti-RFP antibody 
(1:1000, VWR, Radnor PA, USA) and goat anti-ChAT antibody (1:250 Millipore, Etobicoke Ontario, 
Canada). Slices containing neurobiotin injected cells were blocked with donkey serum and incubated with 
streptavidin 546 (1:500) and goat anti-ChAT (1:250). Pairs of secondary antibodies (respectively goat 
Alexa 546 anti-mouse and goat Alexa 488 anti-rabbit, or donkey Alexa 555 anti-rabbit and donkey Alexa 
488 anti-goat, or Alexa 488 anti-goat alone, all purchased from Invitrogen, Carlsbad, CA, USA) were 
incubated for 2 h to reveal specific immunostaining. Images of 5 to 10 µm depth were obtained using an 
Olympus FV1000 confocal microscope using a 20 x water immersion objective and 488 and 543 nm laser 
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excitation. Where appropriate, cells deemed positive for each signal were manually counted using the Cell 
Counter plug-in in ImageJ software (NIH, Bethesda, MD, USA). Percentages of overlapping counts were 
used as indication of signal co-localization. 
Synaptosome preparation and [3H]-acetylcholine release assay 
The synaptosome release assay was performed using the methods of Grady et al. (2001) with minor 
modifications. Mice were killed by cervical dislocation, the brain was rapidly removed, and the dorsal and 
ventral striata were dissected on ice using a mouse brain matrix and a punch tool. The dorsal and ventral 
striata from one mouse were separately homogenized in a glass-teflon homogenizer by 16 strokes by hand 
in 500 µl of ice-cold 0.32 M sucrose buffered to pH 7.5 with 5 mM HEPES. The homogenate, combined 
with two 500 µl rinses of the homogenizer, was centrifuged at 12000 g for 20 min at 4 ºC and the 
resulting pellet was used in the release assay. The synaptosome pellet was resuspended in 400 µl of 
superfusion buffer (in mM: 128 NaCl, 2.4 KCl, 3.2 CaCl2, 1.2 KH2PO4, 1.2 MgSO4, 25 HEPES pH 7.5, 
10 glucose, 0.1 % BSA) and incubated for 30 min at 37 ºC with 8 µCi [3H]choline (0.25 µM). Aliquots of 
40 µl were distributed to parallel filters and superfused in room temperature with superfusion buffer at 0.8 
ml/min. Superfusion was continued for ten min, and release was stimulated using an isotonic 20 mM 
potassium solution (20 mM K+). Varying concentrations of the drugs of interest were present in the 
superfusion buffer after five min of superfusion. The perfusate was collected on 96-well plates in 10 
second (~130 µl) fractions, OptiPhase Supermix scintillation cocktail (100 µl/well; PerkinElmer, Boston, 
MA, USA) was added, and radioactivity was measured with liquid scintillation counting (1 min per well; 
1450 MicroBeta TriLux; Wallac, Turku, Finland). Drug effects on basal [3H]acetylcholine release were 
determined by summing the radioactivity (counts per min, CPM) released during the six fractions (one 
min) immediately before K+ stimulation. Drug effects on K+-stimulated [3H]acetylcholine release were 
determined by summing the radioactivity released during six fractions beginning from the onset of the K+ 
stimulation. The instrument background level of 10 CPM (10–20 % of basal release) was subtracted from 
all fractions. All radioactivity measurements were normalized to the wet tissue weight of the samples, and 
results are presented as CPM/mg tissue. 
Statistical analysis.  
Statistical comparisons were carried out with Prism 6 (GraphPad Software Inc. La Jolla, CA, USA); 
significance level was set at 0.05. All data samples were tested for normal distribution to choose between 
parametric versus non parametric statistics and to represent population parameters either as mean ± 
standard error (SEM) or as median with percentile range; figure legends state the specific test employed 
in each case. To estimate the rate of dopamine re-uptake, a single exponential model was fitted to the 
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single pulse evoked dopamine transients from the peak to the end of the signal (Yorgason et al., 2011); 
the down stroke of the transient is known to represent the clearance of dopamine by concurrent reuptake 





We first examined electrically-evoked dopamine overflow in the ventral and dorsal striatum in order to 
provide a baseline against which to compare the effects of histamine H3 receptor activation. 
Representative voltammograms and traces of dopamine overflow peaks evoked by single electrical pulses 
and paired pulses are depicted in Figure 1 and Table 1. Oxidation and reduction peaks were respectively 
detected at approximately +345 and -180 mV, and the maximal amplitude and time course of the detected 
electroactive substance was greatly enhanced by the dopamine transporter blocker nomifensine (5 µM, 
not shown), used here as a positive control, confirming the identity of the electroactive molecule as 
dopamine. Average single-pulse evoked dopamine overflow in the dorsal striatum was 0.39 ± 0.04 µM, 
with a paired-pulse ratio of 0.06 ± 0.01 and peak half-life of 0.43 ± 0.05 s (Table 1, Fig. 1A-1C). In the 
ventral striatum, dopamine overflow evoked by single pulses averaged 0.31 ± 0.03 µM, with a paired 
pulse ratio of 0.26 ± 0.03 and peak half-life of 0.66 ± 0.05 s (Table 1, Fig. 1D-1F). Although there were 
no significant differences in dopamine overflow between dorsal and ventral striatum (t(73) = 1.573, P = 
0.1201, Table 1), the paired-pulse ratio and peak half-life were significant greater in the ventral striatum 
(paired pulse ratio t(73) = 4.679, P < 0.0001 and peak half-life t(70) = 3.254, P = 0.0018, Table 1). The 
difference in paired pulse ratio observed here is in line with previously published studies (i.e.: Zhang et 
al., 2009) and could be due to a lower probability of release in the ventral compared to the dorsal striatum. 
It should be noted, however, that dopamine overflow levels in dorsal striatum is generally found to be 
higher than in the ventral striatum (i.e.: Zhang et al., 2009; Calipari et al., 2012) whereas, in the present 
study, although the tendency was in this direction, there were no significant differences. Our finding of a 
longer peak half-life in the ventral compared to the dorsal striatum is in line with previous observations of 
lower uptake rates in the ventral striatum (Calipari et al., 2012). 
Histamine H3 receptor activation reduces dopamine release in the ventral striatum, but not in the dorsal 
striatum. 
We next examined the effects of the histamine H3 receptor agonist α-methylhistamine (1 µM) and the 
inverse agonist thioperamide (10 µM) on dopamine overflow evoked by electrical stimulation of dorsal 
and ventral striata. Dopamine overflow evoked by single electrical pulses were stable through the 
experiment (Fig 1G and 1H, open circles). In the dorsal striatum, application of either α-methylhistamine 
or thioperamide failed to alter dopamine overflow evoked by single electrical pulses (two-way RM 
ANOVA effect of treatment: F(2, 26) = 1.652, P = 0.2112, Fig 1G). In the ventral striatum, however, α-
methylhistamine significantly reduced dopamine overflow evoked by single electrical pulses (two-way 
RM ANOVA effect of treatment: F(3, 42) = 2.912, P = 0.0454, Fig 1H, red circles). While thioperamide did 
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not affect dopamine overflow on its own (Fig 1H, black circles), it blocked the effects of α-
methylhistamine (Fig 1H, magenta circles). 
Histamine H3 receptor mRNA is expressed by striatal cholinergic interneurons, but not by mesencephalic 
dopaminergic neurons. 
We considered two possible sites for histamine H3 receptor-mediated reduction of dopamine release. 
First, since numerous studies indicate that these receptors are found in axons and act as hetero-receptors 
capable of decreasing neurotransmitter release (Clapham and Kilpatrick, 1992; Yamamoto et al., 1997; 
Brown and Haas, 1999; Threlfell et al., 2004), we hypothesized that these receptors are expressed by 
dopamine neurons and reduce dopamine release by directly inhibiting dopaminergic axon terminals. 
Second, since electrical stimulation of the striatum causes the release of acetylcholine which, in turn, 
activates nicotinic receptors present on dopaminergic axon terminals and boosts dopamine release 
(Cachope et al., 2012; Threlfell et al., 2012), we hypothesized that activation of histamine H3 receptors on 
cholinergic interneurons could result in their inhibition and decreased cholinergic tone on dopaminergic 
axon terminals, hence indirectly reducing dopamine release. We started investigating these hypotheses by 
quantifying expression of histamine H3 mRNA in mesencephalic dopaminergic neurons and striatal 
cholinergic interneurons. Male and female TH-GFP mice were used for FACS purification of 
dopaminergic neurons. Cholinergic interneurons were purified by FACS from VGluT3-tdTomato mice. 
RT-qPCR on cell-sorted samples indicated that H3 receptor mRNA is expressed at similar levels by 
VGluT3-tdTomato neurons harvested from the dorsal and ventral striatum (Table 2, t5 = 1.100, P = 
0.3315). In contrast, no amplification products of H3 receptor mRNA were detected in TH-GFP neurons 
harvested in the mesencephalon (Table 2). Given that amplification of the reference mRNA, GAPDH, 
was seen at similar levels in all samples (Kruskal-Wallis = 4.805, P = 0.1916) we concluded that H3 
receptor mRNA is absent or expressed at only very low levels by mesencephalic dopaminergic neurons. 
These data argue against a direct regulation of dopaminergic axon terminals by H3 receptors. 
Histamine H3 receptors do not modulate dopamine release directly from dopaminergic axons 
Electrical stimulation of brain slices causes numerous neurotransmitters to be released simultaneously, 
and their interaction may act as potential confounding factors on determining the site of action for a 
particular substance. To avoid this issue, we employed optogenetics to selectively stimulate dopaminergic 
axons in the ventral striatum. We hypothesized that if histamine H3 receptors do not reside on 
dopaminergic axons their effect on dopamine release should be absent when dopamine release is triggered 
by selective stimulation of these axons. To this end we injected a viral vector containing double-inverted 
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open reading frame coding for channelrhodopsin-2-eYFP (ChR2-eYFP) into the VTA of DAT-cre male 
mice. Expression of ChR2-eYFP was limited to the mesencephalon-striatum, and restricted to tyrosine-
hydroxylase (TH) containing neurons (Fig 2A, upper panels). On average, 72 ± 3 % of TH positive 
neurons were found to express ChR2-eYFP protein. As expected, the ventral striatum had enriched 
expression of ChR2-eYFP signal in dopaminergic axon terminals (Fig 2A, bottom panels). Figure 2B and 
2C depict voltammograms after optical stimulation by a single-pulse of blue light (1 ms, 20 mW). Light-
evoked dopamine overflow peaks averaged 0.32 ± 0.04 µM, with a paired pulse ratio of 0.53 ± 0.03 and 
peak half-life of 0.89 ± 0.09 seconds. Responses were completely blocked by TTX (Fig 2 C-D), 
confirming they were action-potential dependent. Evoked dopamine overflow was stable for the duration 
of the experiment (Fig 2E). Neither the histamine H3 agonist α-methylhistamine nor its inverse-agonist 
thioperamide altered optogenetically evoked dopamine release triggered by single light pulses (two-way 
RM ANOVA effect of treatment: F(2, 21) = 0.5555, P = 0.5820, Fig 2E) In addition, none of the drugs 
affected the paired-pulse ratio or peak-decay kinetics. These results indicate that histamine H3 receptors 
do not modulate dopamine release by acting directly on dopaminergic axon terminals. 
Modulation of ventral-striatal dopamine release by histamine H3 receptors is mediated by acetylcholine 
To test if histamine H3 receptor-inhibition of electrically-evoked dopamine release is mediated by 
acetylcholine, we electrically stimulated ventral striatal slices in presence of the nicotinic acetylcholine 
receptor blocker dihydro β-erythroidine (DHβE, 1 µM). Figures 3A and 3B illustrate voltammograms in 
absence and presence of DHβE. Blockade of high affinity nicotinic receptors reduced dopamine overflow 
to about 37 ± 7 % of its initial value (two-way RM ANOVA time and treatment interaction: F(12, 48) = 
10.66, P < 0.0001, Fig 3C-E). Once nicotinic receptor blockade was established, evoked dopamine 
overflow was stable through the rest of the experiment. The presence of DHβE occluded the effects of α-
methylhistamine on dopamine overflow evoked by single electrical pulses (two-way RM ANOVA effect 
of treatment: F(2, 22) = 0.7979, P = 0.4629 Fig 3F). This was unlikely to be due to any floor effect, as levels 
detected in the presence of DhβE were still quite substantial and with a high signal to noise ratio (Fig 3D). 
These results are compatible with a role for acetylcholine in mediating the effects of α-methylhistamine 
on ventral striatal dopamine release. 
Histamine H3 receptor activation decreases spontaneous cholinergic interneuron activity in the ventral, 
but not in the dorsal striatum. 
 16 
 
 Striatal cholinergic interneurons were identified by the presence of VGluT3-tdTomato (ventral striatum) 
or by cell morphology and electrophysiological characteristics (dorsal striatum). In both cases, cells 
exhibited typical spontaneous activity (representative traces in Fig 4B and 5A).  
In the ventral striatum, event frequency was significantly reduced in response to α-methylhistamine (two-
way RM ANOVA effect of treatment: F(2, 25) = 4.071, P = 0.0295 Fig 4C). Post-hoc analysis confirmed a 
sustained reduction of event frequency by α-methylhistamine, whereas with thioperamide, only a transient 
increase was observed at 10 min after drug application. Stratification of event frequencies indicated that 
α-methylhistamine increased the occurrence of time bins without events by about 4-fold (two-way RM 
ANOVA interaction of treatment and frequency bin: F(22, 275) = 2.058, P = 0.0042, Fig 4D). These results 
suggest that the spontaneous activity of cholinergic interneurons in the ventral striatum is modulated by 
histamine H3 receptors, and that activation of these receptors changes the activity profile of these 
interneurons to one that favors lower-frequency firing. 
In the dorsal striatum neither application of α-methylhistamine nor thioperamide altered spontaneous 
firing of cholinergic interneurons (two-way RM ANOVA for treatment: F(2, 23) = 1.127, P = 0.3414, Fig 
5C). These results reinforce the notion that the effects of histamine H3 modulation of cholinergic 
interneuron activity are specific to the ventral striatum. 
Local activation of histamine H3 receptors in ventral striatal cholinergic interneurons decreases resting 
membrane potential and spontaneous firing 
We further investigated the effects of H3 receptor activation on ventral striatal cholinergic interneurons 
using the whole cell patch-clamp technique. Cells obtained from male C57BL/6 mice were identified by 
their morphology and the identity was confirmed, post-hoc, by filling the cells with neurobiotin and co-
immunostaining against ChAT (Fig 6A). Once in whole-cell mode, these cells exhibited capacitance 
varying from 60 to 150 pF, resting membrane potential of approximately -55 mV and spontaneous action 
potentials, characteristics typical of striatal cholinergic interneurons. Stable firing activity was monitored 
for at least five min, after which a 1min baseline was recorded (representative traces in Fig 6B). To 
improve temporal resolution of the drug effects, we performed application of α-methylhistamine by 
ejecting the drug through a locally placed pipette over a 30s period. Applying α-methylhistamine in this 
manner resulted in a significant decrease of resting membrane potential (two-way RM ANOVA, 
significant time vs. treatment interaction: F(1, 12) = 182.0, P < 0.0001, Fig 6C) and in the number of 
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spontaneous action potentials (two-way RM ANOVA significant time vs. treatment interaction: F(1, 12) = 
21.17, P = 0.0006, Fig 6D). 
Histamine H3 receptors activation does not reduce acetylcholine release from isolated striatal nerve 
endings 
Last, we used isolated synaptosome preparations to assess whether histamine H3 receptors modulate 
acetylcholine release directly from striatal nerve endings (Fig. 7). We hypothesized that, should these 
receptors be present in cholinergic axon terminals, H3 receptor agonist stimulation should reduce 
[3H]acetylcholine release from synaptosomes, measured as radioactive counts per minute (CPM) 
normalized to tissue mass. The H3 receptor agonist α-methylhistamine had no significant effects on either 
basal [3H]acetylcholine release (one-way ANOVA: ventral striatum F3,28 = 0.04, P = 0.990 Fig 7D; dorsal 
striatum F3,28 = 0.0671, P = 0.9769, Fig 7A) or K+-stimulated [3H]acetylcholine release (one-way 
ANOVA: ventral striatum F3,28 = 0.0458, P = 0.9867, Fig 7D; dorsal striatum F3,28 = 0.0038, P = 0.9997, 
Fig 7A). Surprisingly, the highest concentration of the H3 receptor inverse agonist thioperamide 
significantly decreased basal [3H]acetylcholine release from ventral striatum synaptosomes (one-way 
ANOVA followed by Dunnett: F3,24 = 3.108, P = 0.0453, Fig 7E) but not from the dorsal striatal 
synaptosomes (one-way ANOVA: F3,24 = 0.5148, P = 0.6760, Fig 7B). Thioperamide had no significant 
effects on K+-stimulated [3H]acetylcholine release either in from ventral (one-way ANOVA: F3,24 = 
0.9539, P = 0.4304, Fig 7E) or dorsal (F3,24 = 0.0884, P = 0.9657, Fig 7B) striatal synaptosomes. The D2 
receptor agonist apomorphine was used as a control, as dopaminergic agonists have previously been 
shown to inhibit acetylcholine release from rodent striatal slices and synaptosomes (de Belleroche et al., 
1982). Apomorphine (100 µM) significantly decreased basal [3H]acetylcholine release from both the 
ventral striatal (Student’s “t” test: t(28) = 5.91, P < 0.0001, Fig 7F) and the dorsal striatal (Student’s “t” 
test: t(28) = 3.186, P < 0.0035, Fig 7C) synaptosomes, and also significantly inhibited K+-stimulated 
release from ventral striatal (Student’s “t” test: t(28)  = 4.547, P < 0.0001, Fig 7F), but not dorsal striatal 





The central finding of the present study is that activation of histamine H3 receptors by α-methylhistamine 
reduced electrically evoked dopamine overflow in the ventral striatum of mice. This effect was 
completely blocked by simultaneous application of thioperamide, an inverse-agonist of H3 receptors, 
confirming that H3 receptors were selectively activated. Further, α-methylhistamine did not alter 
dopamine overflow half-life or the paired pulse ratio, indicating that the reduced dopamine overflow was 
not due to increased uptake/diffusion or to reduced pre-synaptic vesicle mobilization. Our work suggests 
that regulation of dopamine release by H3 receptors was caused not by a direct heterosynaptic inhibition 
of dopaminergic axon terminals, but rather by inhibition of the firing of striatal cholinergic interneurons, 
leading to reduced nicotinic facilitation of dopamine release. In favor of this model, we found that H3R 
mRNA is absent from dopamine neurons and that the H3 agonist had no effect on dopamine overflow 
evoked by direct optogenetic stimulation of dopaminergic axons. Conversely, we found measurable levels 
of H3R mRNA in striatal cholinergic interneurons and that the nicotinic acetylcholine receptor antagonist 
DHβE occluded the effects of α-methylhistamine on electrically evoked dopamine overflow. We also 
showed that α-methylhistamine dramatically reduced the spontaneous firing of ventral striatal cholinergic 
interneurons, but did not reduce acetylcholine release from acutely isolated synaptosomes, suggesting that 
the observed modulation of dopamine overflow is probably mediated by H3 receptors located in the 
somatodendritic compartment of cholinergic interneurons, rather than at their axon terminals. 
To our knowledge, this is the first study to directly investigate activity-dependent H3-receptor modulation 
of dopamine release in the mouse striatum using voltammetric measurements of dopamine overflow. This 
technique offers key advantages given the fast kinetics of activity-dependent evoked dopamine transients 
in the striatum that might otherwise be missed by traditional techniques such as microdialysis. Our data 
are compatible with the increasing evidence suggesting that histamine plays a modulatory role upon 
dopaminergic neurotransmission, both in mice and other rodents. In an earlier study, Schlicker et al. 
(1993) demonstrated that histamine causes a discrete reduction of electrically-evoked [3H]dopamine 
release from mouse striatal slices, an effect mimicked by α-methylhistamine and blocked by thioperamide 
at the same concentrations of those used here. Subsequent studies indicated that histamine H3 receptors 
fail to affect baseline levels of dopamine (Fox et al., 2005; Giannoni et al., 2010; Aquino-Miranda et al., 
2015), but reliably modulate extracellular dopamine elevations evoked by pharmacological stimuli 
(Munzar et al., 2004; Nowak et al., 2008; Alfaro-Rodriguez et al., 2013). In addition, H3 receptors have 
been shown to modulate behaviors typically regulated by dopaminergic neurotransmission, such as 
alcohol consumption reinstatement (Nuutinen et al., 2015), alcohol-mediated reward (Nuutinen et al., 
2011; Morais-Silva et al., 2016), amphetamine self-administration (Munzar et al., 2004), amphetamine-
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induced locomotor activity (Munzar et al., 2004; Banks et al., 2009), apomorphine-induced turning 
behavior in mice with unilateral striatal ablation (Garcia-Ramirez et al., 2004), among others. It is 
important to point out, however, that other uncontrolled parameters perhaps exist influencing how these 
receptors act to regulate the dopaminergic system under different experimental conditions. At least for 
studies performed using brain slices, a key parameter may be the viability and excitability of cholinergic 
interneurons. In the present experiments, we employed a novel protective slicing technique (Peca et al., 
2011; Zhao et al., 2011; Ting et al., 2014). Although a systematic comparison between slicing methods 
was beyond the scope of the present study, we empirically found that experimental reproducibility 
improved with the new method in comparison with more traditional brain slice preparation methods. We 
postulate that increased interneuron viability in these slices may have been relevant for the results 
observed, especially since experiments were performed in adult mice. 
Our results suggest that H3-mediated reduction of dopamine release is achieved indirectly by reducing the 
firing of cholinergic interneurons and reducing basal cholinergic tone. This could lead to a reduced 
efficacy of electrically-evoked acetylcholine release to trigger dopamine release, but further experiments 
would be needed to determine this. The link between acetylcholine release and dopamine release has been 
the focus of multiple recent studies (Zhou et al., 2001; Cachope et al., 2012; Threlfell et al., 2012; see de 
Kloet et al., 2015 for a recent review). Optogenetic activation of striatal cholinergic interneurons can 
directly trigger dopamine release from dopaminergic axon terminals in both the ventral and dorsal 
striatum (Threlfell et al., 2012). Furthermore, acetylcholine released from cholinergic interneurons and 
other cholinergic terminals in the striatum activates β2 subunit-containing nicotinic receptors in 
dopaminergic axons that, in turn, allow influx of Na+, leading to depolarization of these axons and 
exocytosis of dopamine. Therefore, it is logical to hypothesize that drugs capable of regulating 
cholinergic tone may also affect dopamine release. This view is supported by the fact that local 
inactivation of H3 receptors increased acetylcholine release in vivo (Prast et al., 1994). Interestingly, our 
results indicate that although striatal cholinergic neurons contain H3R mRNA, H3 receptors do not 
modulate acetylcholine release from isolated striatal synaptosomes, perhaps indicating that these receptors 
are somatodendritic. Although it is possible that the synaptosome assay we used was not sufficiently 
sensitive to detect a H3-mediated inhibition of acetylcholine release, our results with the dopamine 
receptor agonist apomorphine provide a positive control showing that our experimental conditions 
allowed for detection of modest levels of acetylcholine release inhibition. Moreover, our observations are 
compatible with previous work indicating that striatal H3 receptors are predominantly post-synaptic rather 
than pre-synaptic (i.e. Ferrada et al., 2009; Moreno et al., 2011; reviewed by Ellenbroek and Ghiabi, 
2014). We cannot exclude, however, that reduced cholinergic interneuron activity resulted from inhibition 
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of glutamatergic inputs onto these neurons. Indeed, previous studies point out that histamine H3 receptors 
depress striatal glutamate release (Doreulee et al., 2001; Molina-Hernandez et al., 2001; Ellender et al., 
2011), and that glutamatergic tone is pivotal for cholinergic regulation of striatal dopamine release 
(Kosillo et al., 2016).  
Modulation of striatal glutamate has also been shown to regulate dopamine release (Bennett and Gronier, 
2005; David et al., 2005; Beurrier et al., 2009), and changes in the recruitment of cholinergic 
interneurons, although not directly investigated in these studies, cannot be ruled out. Cholinergic 
interneurons also express VGluT3 and are capable of releasing glutamate (Higley et al., 2011) and may 
decrease local glutamate release via mGluR activation (Sakae et al., 2015). Yet, given that of α-
methylhistamine was no longer effective in the presence of DhβE, we interpret these results as a 
cholinergic rather than a glutamatergic effect. Clearly, the effects of H3 receptor activation/inactivation on 
more detailed electrophysiological parameters of cholinergic interneurons, such as resting membrane 
potential and excitatory and inhibitory inputs as well as the direct consequence for evoked acetylcholine 
release and for cholinergic/glutamatergic neurotransmission should be the subject of further investigation. 
We found that thioperamide transiently increased the spontaneous activity of cholinergic interneurons in 
the ventral striatum. Given this effect, one would expect to find a similar outcome when measuring 
dopamine release evoked by single electrical pulses. However, that was not the case. We speculate that 
the effects of thioperamide and the related basal level of activation of H3 receptors that it may block may 
have been too small to be picked up in this assay, or that the receptor may be subject to rapid 
desensitization upon prolonged exposure to the inverse agonist.  
An intriguing observation of the present study is the lack of effect of histamine H3 drugs in the dorsal 
striatum. This is particularly surprising in light of previous radioligand binding studies and in-situ 
hybridization suggesting that the dorsal striatum is one of the brain structures with the highest density of 
H3 receptors (Jansen et al., 2000; Pillot et al., 2002). In rats, striatal H3R mRNA was found to co-localize 
with markers for cholinergic interneurons and with D1- and D2-expressing medium spiny neurons 
(González-Sepúlveda et al., 2013). Here, we found that H3R mRNA is present in dorsal-striatal 
cholinergic interneurons at levels similar to those found in the ventral striatum. Thus, lack of H3 receptor 
expression by cholinergic neurons cannot readily explain the failure of histamine H3 drugs to modulate 
dopamine release in the dorsal striatum. In addition, blockade of β2 subunit-containing nicotinic receptors 
was previously shown to reduce dorsal striatal dopamine overflow to an extent similar to that seen in the 
ventral striatum (Salinas et al., 2016), thus ruling out a disconnection between cholinergic and 
dopaminergic systems in this region. It should be taken into account, however, that presence of mRNA 
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does not warrant quantifiable levels of its respective protein, and nicotinic modulation of dopamine 
overflow in dorsal striatum will not guarantee that crosstalk between histamine and acetylcholine is as 
efficient as in the ventral striatum. Therefore, it is still possible that dorsal-striatal cholinergic 
interneurons have fewer H3 receptors, or that these receptors couple less efficiently to their signaling 
effectors. Finally, it remains to be investigated whether activation of H3 receptors in such interneurons 
will lead to membrane hyperpolarization and reduced firing to a degree similar to that observed here in 
the ventral striatum.  
In rats, evidence shows that dopaminergic neurons express H3R mRNA (González-Sepúlveda et al., 
2013). Here, we did not find detectable levels of H3R mRNA in dopaminergic neurons harvested either 
from the VTA or SN of mice. The lack of any observable effect of H3 receptor activation on 
optogenetically evoked dopamine overflow is also compatible with our observation of a lack of 
expression of H3 receptors in dopamine neurons in mice. These findings highlight a possible interspecies 
difference in histamine H3 receptor brain distribution and function. 
Our findings highlight histamine H3 receptors as critical and region-specific regulators of dopamine 
release in the ventral but not the dorsal striatum. Our findings do not exclude other effects of H3Rs in the 
dorsal striatum, as suggested by receptor work suggesting a role for this receptor in sensorimotor gating 
(Kononoff Vanhanan et al., 2016). Nonetheless, considering the major interest in region-specific 
regulation of dopamine release in mesostriatal versus mesolimbic pathways in the context of diseases 
such as drug abuse and schizophrenia, our results suggest that this pathway could represent an interesting 
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Figure 1 Effects of histamine H3 agonist and inverse agonist on dopamine overflow evoked by 
electrical stimuli in the dorsal and ventral striatum. Electrically evoked dopamine levels were detected 
by fast-scan cyclic voltammetry in the dorsal and ventral striatum. Heat maps illustrating the current 
detected as a function of time and applied potential in the dorsal (A) and ventral striatum (D). The vertical 
dotted lines in the heat map indicate the maximum oxidation/reduction peaks for dorsal and ventral 
striatum, and the corresponding cyclic voltammograms are illustrated in (B) and (E). The traces illustrate 
representative dopamine overflow peaks evoked by single and paired electrical stimulation in the dorsal 
(C) and ventral striatum (F). In the dorsal striatum (G) neither the selective H3 agonist α-methylhistamine 
(red circles) nor the selective H3 inverse agonist thioperamide (black circles) affected dopamine overflow 
evoked by single electrical pulses. In the ventral striatum (H), α-methylhistamine (red circles) 
significantly reduced dopamine overflow evoked by single electrical pulses, an effect prevented by 
concomitant application of thioperamide (magenta circles). Thioperamide alone (black circles) did not 
affect dopamine overflow evoked by single electrical pulses in the ventral striatum. Gray bars indicate the 
period when drugs were present. Data were analyzed by two-way RM-ANOVA followed by Sidak. * P < 
0.05, ** P < 0.01, *** P < 0.001 when compared to controls. 
Figure 2 Effects of histamine H3 agonist and inverse agonist on optogenetically evoked dopamine 
overflow in the ventral striatum. Coronal sections containing the mesencephalon (A, upper panels) or 
ventral striatum (A, bottom panels) were obtained 4 weeks after injection of AAV5-DIO-EF1α-ChR2-
(H134R)-EYFP into the VTA of DAT-Cre +/- mice. Sections were stained against the dopamine neuron 
marker tyrosine hydroxylase (TH, red channel) and the transfected ChR2-eYFP protein (green channel). 
Merged images indicate selective virus expression in dopamine cell bodies (upper right panels) and their 
axons (bottom right panels). White calibration bar indicates 50 µm. Illuminating the slice with a single 
light-pulse of 1 ms duration caused dopamine overflow to be observed in the fast-scan cyclic voltammetry 
heat map (B). Cyclic voltammograms are presented in (C), and representative traces of light-evoked 
dopamine overflow are shown in (D). The sodium channel blocker tetrodotoxin (TTX, red traces) 
completely blocked dopamine release induced by the optical stimuli (C-D). Next, a baseline was recorded 
for each drug condition. Each circle or bar represents the mean ± SEM normalized to that baseline. 
Neither α-methylhistamine (red circles/bar) nor thioperamide (black circles/bar) affected dopamine 
overflow evoked either by single light pulses (E) or by 2-s trains (F). Data were analyzed by two-way RM 
ANOVA (E) or one-way ANOVA (F). No statistically significant effects were observed (P > 0.05). 
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Figure 3 Effects of nicotinic acetylcholine receptor blockade on histamine H3-mediated reduction of 
electrically-evoked dopamine overflow. Fast-scan cyclic voltammetry heat maps illustrate the current 
detected as a function of time and the applied potential during baseline (A) or under blockade of nicotinic 
acetylcholine receptors by dihydro-β-erythrodine (DHβE) (B). Cyclic voltammograms detected are 
represented in (C). Representative traces illustrating peak dopamine overflow are illustrated in (D). DHβE 
reduced the magnitude of electrically-evoked dopamine overflow to about 37% of its initial value (E) and 
was stable for the duration of the entire experiment. A baseline was recorded for each condition under 
nicotinic blockade and all subsequent results were normalized to that baseline (F). No significant effect of 
α-methylhistamine (red circles) was detected on dopamine overflow evoked by single pulse stimulation in 
the presence of DHβE. Data were analyzed by two-way RM ANOVA (E-F). No statistically significant 
effects were observed (P > 0.05). 
Figure 4 Effects of histamine H3 receptor agonist and inverse agonist on spontaneous firing activity 
of ventral striatal cholinergic interneurons. Coronal sections of the ventral striatum of mice expressing 
the tdTomato fluorescent protein in Vglut3-containing neurons allowed for identification of cholinergic 
interneurons (A). Sections were stained against tdTomato (red channel, upper panel) and the cholinergic 
marker choline acetyl transferase (ChAT, green channel, middle panel). Merged images (bottom panel) 
confirm that Vglut3-Tomato cells are indeed cholinergic interneurons. Spontaneous cell firing measured 
by loose-cell attached electrophysiology (representative recording in B, upper trace) was reduced by the 
selective H3 agonist α-methylhistamine (bottom trace). Event frequency was normalized to a 5 min 
baseline and binned in 1 min intervals (C). α-Methylhistamine (red circles) significantly reduced the 
frequency of spontaneous events, while the selective H3 inverse-agonist only transiently increased event 
frequency when compared to controls. Stratification of events by their instantaneous frequency during the 
last 5 min of recording (D) indicates that α-methylhistamine (red bars) increases the proportion of events 
with frequency between 0.01 and 0.5 Hz, while thioperamide (black bars) tended to increase the 
predominance of events with frequency greater than 6 Hz (P = 0.0528). All data are represented as the 
mean ± SEM normalized to the baseline (C) or the total number of events for each category bin (D). All 
results were analyzed by two-way RM ANOVA followed by Sidak. * P < 0.05, ** P < 0.01 or *** P < 
0.001 when compared to controls.  
Figure 5 Effects of histamine H3 receptor agonist and inverse agonist on spontaneous firing activity 
of dorsal striatal cholinergic interneurons. Spontaneous firing was measured by loose-cell attached 
patch recording (representative traces in A). Event frequency was normalized to a 5 min baseline and 
binned in 1 min intervals (B). Neither α-Methylhistamine (red circles) nor Thioperamide (black circles) 
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altered the frequency of spontaneous events (two-way RM ANOVA, P > 0.05). The grey bar indicates the 
period of drug treatment. 
Figure 6 Effects of local application of the H3 receptor agonist α-methylhistamine on resting 
membrane potential and spontaneous action potentials of ventral striatal cholinergic interneurons. 
Cholinergic interneurons were initially identified by cell morphology and electrophysiological properties, 
and the identity of some cells was confirmed by co-immunostaining neurobiotin-filled cells with a ChAT 
antibody (A). Recorded neurons exhibited a resting membrane potential of approximately -55 mV and 
spontaneous action potentials (AP), typical of cholinergic interneurons (representative trace in B). 
Ejection of α-methylhistamine through a locally placed pipette (duration of drug ejection represented by a 
gray bar) significantly reduced the resting membrane potential (C) and frequency of spontaneous APs 
(D). Scale bars in A indicate 20 µm. All results were analyzed by two-way RM ANOVA followed by 
Sidak. *** P < 0.001 or **** P < 0.0001 when compared to pre-drug baseline. 
Figure 7 Effects of H3 and D2 ligands on the release of [3H]acetylcholine from mouse ventral and 
dorsal striatum synaptosomes. Synaptosomes prepared separately from samples of ventral and dorsal 
striatum were loaded with [3H]choline, incubated for 30 min and superfused for ten minutes prior to 
stimulating release with 20 mM K+. Thioperamide, α-methylhistamine or apomorphine were present after 
five min of superfusion. Graphs show radioactivity (CPM/mg tissue; mean ± SEM) released immediately 
before stimulation (basal) as well as immediately after stimulation (stimulated). The H3 agonist α-
methylhistamine had no effect on basal or stimulated release (A, D). The H3 inverse agonist thioperamide 
inhibit basal [3H]acetylcholine release from the ventral striatal synaptosomes, but only at the highest dose 
tested (E). No effect was detected on dorsal striatal synaptosomes (B). The D2 agonist apomorphine 
significantly inhibited basal [3H]acetylcholine release from both dorsal (C) and ventral (F) striatal 
synaptosomes, and also reduced stimulated release from ventral striatal synaptosomes (F). Results were 
analyzed by one-way ANOVA followed by Dunnett’s test (A-B, D-E) or by Student’s t test (C and F). * P 





Table 1: Summary of electrically-evoked dopamine-overflow in dorsal and ventral striatum 
 Dorsal striatum (n) Ventral striatum (n) P value 
Single-pulse DA peak amplitude (µM) 0.39 ± 0.04 (29) 0.31 ± 0.03 (46) 0.1201 
Paired-pulse ratio [(2nd - 1st)/1st ] 0.06 ± 0.01 (29) 0.26 ± 0.03 (46) < 0.0001 





Table 2: Quantification of H3R mRNA in striatal ACh interneurons and mesencephalic DA neurons 
 Striatal ACh interneurons Mesencephalic DA neurons 
Dorsal striatum Ventral striatum SN VTA 
H3R mRNA Ct 32.07 (30.92, 32.42) 31.42 (30.34, 32.61) n.d. n.d. 
GAPDH Ct 23.68 (22.8, 24.23) 23.16 (22.76, 25.48) 25.54 (24.23, 26.33) 23.86 (22.79, 25.34) 
2-ΔΔCt 1.082 (0.704, 1.313) 1.809 (0.718, 2.947) n/a n/a 
 
Values presented as “median (25% percentile, 75% percentile)” 
n.d.: Not detected 
n/a: Not applicable 
Sample sizes: Dorsal striatum = 3; Ventral striatum = 4; SN = 4; VTA = 3. 
